Biocept ( ) - 株価, ニュースと分析Nasdaq:BIOC

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BIOC 株式概要

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States.

会社概要

BIOC fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

報酬

収益は年間67.14%増加すると予測されています

リスク分析

意味のある時価総額がありません ( $3M )

過去1年間で株主の希薄化は大幅に進んだ

過去3か月間の株価の変動は非常に激しい

キャッシュランウェイが1年未満である

+2 さらなるリスク

Biocept, Inc. 競合他社

AXIM Biotechnologies

OTCPK:AXIM

US$2.4m

Ensysce Biosciences

NasdaqCM:ENSC

US$3.9m

OpGen

NasdaqCM:OPGN

US$3.4m

Azitra

NYSEAM:AZTR

US$4.3m

価格と性能

Summary of all time highs, changes and price drops for Biocept
Historical stock prices
Current Share Price	US$1.02
52 Week High	US$27.00
52 Week Low	US$0.80
Beta	0.59
1 Month Change	-38.92%
3 Month Change	-13.56%
1 Year Change	-95.67%
3 Year Change	-99.28%
5 Year Change	-99.85%
Change since IPO	-100.00%

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13

株主還元

	BIOC	US Biotechs	US 市場
7D	-3.8%	-2.0%	1.6%
1Y	-95.7%	5.4%	21.5%

業界別リターン: BIOC過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: BIOCは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement	20.9%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

安定した株価: BIOCの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: BIOCの weekly volatility ( 21% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1997	50	Antonino Morales	biocept.com

Biocept, Inc. 基礎のまとめ

Biocept の収益と売上を時価総額と比較するとどうか。
BIOC 基礎統計学
時価総額	US$2.68m
収益（TTM）	-US$30.61m
売上高(TTM)	US$1.36m

2.0x

P/Sレシオ

-0.1x

PER（株価収益率

BIOC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
BIOC 損益計算書（TTM）
収益	US$1.36m
売上原価	US$15.66m
売上総利益	-US$14.30m
その他の費用	US$16.30m
収益	-US$30.61m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-11.66
グロス・マージン	-1,054.09%
純利益率	-2,255.49%
有利子負債／自己資本比率	181.4%

BIOC の長期的なパフォーマンスは？

過去の実績と比較を見る

BIOC 株式概要

報酬

リスク分析

Biocept, Inc. 競合他社

OTCPK:AXIM

US$2.4m

NasdaqCM:ENSC

US$3.9m

NasdaqCM:OPGN

US$3.4m

NYSEAM:AZTR

US$4.3m

価格と性能

最新ニュース

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

No longer forecast to breakeven

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Investor sentiment improved over the past week

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Consensus revenue estimates increase to US$37.5m

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Price target decreased to US$12.00

Biocept enters COVID-19 testing partnership

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: US$6.70

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

New 90-day high: US$6.23

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint